BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32444980)

  • 1. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma.
    Bergman D; Modh A; Schultz L; Snyder J; Mikkelsen T; Shah M; Ryu S; Siddiqui MS; Walbert T
    J Neurooncol; 2020 Jun; 148(2):353-361. PubMed ID: 32444980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
    Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
    J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes.
    Bovi JA; Prah MA; Retzlaff AA; Schmainda KM; Connelly JM; Rand SD; Marszalkowski CS; Mueller WM; Siker ML; Schultz CJ
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):979-986. PubMed ID: 32599030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fractionated stereotactic radiosurgery for malignant gliomas: comparison with single session stereotactic radiosurgery.
    Choi SW; Cho KR; Choi JW; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2019 Dec; 145(3):571-579. PubMed ID: 31705245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.
    Arvold ND; Shi DD; Aizer AA; Norden AD; Reardon DA; Lee EQ; Nayak L; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Wen PY; Alexander BM
    J Neurooncol; 2017 Dec; 135(3):581-591. PubMed ID: 28975467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment.
    Shi W; Blomain ES; Siglin J; Palmer JD; Dan T; Wang Y; Werner-Wasik M; Glass J; Kim L; Bar Ad V; Bhamidipati D; Evans JJ; Judy K; Farrell CJ; Andrews DW
    J Neurooncol; 2018 Mar; 137(1):171-177. PubMed ID: 29235052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma.
    Lee YP; Jung HA; Lee MS; Choi JW; Kong DS; Seol HJ; Nam DH; Lee JI; Lee SH
    J Neurooncol; 2022 Feb; 156(3):541-549. PubMed ID: 35094201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated Radiosurgery Plus Bevacizumab for Locally Recurrent Brain Metastasis with Previously High-Dose Irradiation.
    Guan Y; Wang C; Zhu H; Li J; Xu W; Sun L; Pan L; Dai J; Wang Y; Wang E; Wang X
    World Neurosurg; 2020 Jan; 133():e252-e258. PubMed ID: 31505283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
    Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
    Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with ("pseudo-randomized") treatment allocation by the health insurance provider.
    Hofmann S; Schmidt MA; Weissmann T; Eyüpoglu I; Strnad A; Semrau S; Fietkau R; Putz F; Lettmaier S
    J Neurooncol; 2020 Jun; 148(2):373-379. PubMed ID: 32409944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
    Antoni D; Jastaniah Z; Haoming QC; Gaultier C; Ahle G; Couchot J; Atlani D; Schott R; Clavier JB; Srour R; Chaussemy D; Noël G
    Cancer Radiother; 2016 Jun; 20(4):282-91. PubMed ID: 27318555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.
    Schnell O; Thorsteinsdottir J; Fleischmann DF; Lenski M; Abenhardt W; Giese A; Tonn JC; Belka C; Kreth FW; Niyazi M
    J Neurooncol; 2016 Dec; 130(3):591-599. PubMed ID: 27599828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
    Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
    Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma.
    Fleischmann DF; Jenn J; Corradini S; Ruf V; Herms J; Forbrig R; Unterrainer M; Thon N; Kreth FW; Belka C; Niyazi M
    Radiother Oncol; 2019 Sep; 138():99-105. PubMed ID: 31252301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.
    Levin VA; Chan J; Datta M; Yee JL; Jain RK
    J Neurooncol; 2017 Sep; 134(2):325-330. PubMed ID: 28631191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
    Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
    J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.
    Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G
    Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
    Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
    J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
    Tsien CI; Pugh SL; Dicker AP; Raizer JJ; Matuszak MM; Lallana EC; Huang J; Algan O; Deb N; Portelance L; Villano JL; Hamm JT; Oh KS; Ali AN; Kim MM; Lindhorst SM; Mehta MP
    J Clin Oncol; 2023 Feb; 41(6):1285-1295. PubMed ID: 36260832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractionated stereotactic radiosurgery with volumetric modulated arc therapy (Rapid Arc) for reradiation in recurrent high grade gliomas.
    Anand AK; Kumar P; Patir R; Vaishya S; Bansal AK; Chaudhoory AR; Punnakal AU; Malhotra H; Munjal RK
    J Cancer Res Ther; 2014; 10(1):97-102. PubMed ID: 24762494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.